Dong-A ST out-licensed its diabetes treatment to a Russian company, Reropharm

Published: 2015-07-22 14:44:27

Updated: 2015-07-22 14:44:32

Dong-A ST(President and CEO Chan-il Park) announced on the 20^th that it has established an out-licensing contract of the new self-developed diabetes treatment, ‘Evogliptin(code name: DA-1229),’ with a Russian company, Geropharm LLC.

Under the contract, Dong-A ST will receive down payment and licensing fees from its development phases along with royalty from sales and additional profits of raw ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.

Dong-A ST out-licensed its diabetes treatment to a Russian company, Reropharm

Dong-A ST(President and CEO Chan-il Park) announced on the 20th that it has established an out-licensing contract of the new self-developed diabetes treatment, ‘Evogliptin(code name: DA-1229),’ with a Russian company, Geropharm LLC.

Fees

Dong-A ST(President and CEO Chan-il Park) announced on the 20^th that it has established an out-licensing contract of the new self-developed diabetes treatment, ‘Evogliptin(code name: DA-1229),’ with a Russian company, Geropharm LLC.